Changes in fair value of contingent consideration liabilities (including 13,424 for the year ended december31, 2023 from related parties)
-
-
0
-
Compensation expense - performance interests
11,791
3,763
-
-
Deferred taxes
-7,326
-19,321
8,909
6,378
Tax receivable agreement liability remeasurement
-
-
-2,914
-
Equity in earnings of joint venture
88
504
595
848
Return on investment in joint venture
-
-
1,200
500
Operating lease right-of-use asset lease expense
7,536
6,877
5,320
12,959
Other
-724
-31
-1,010
-148
Accounts receivable, net
91,853
59,199
-9,378
139,448
Contract assets
27,985
25,711
25,003
46,182
Prepaid expenses and other current assets
1,385
1,549
-1,731
-1,198
Accounts payable
79,153
26,144
23,368
94,542
Accrued compensation and benefits
18,672
24,044
-22,057
34,355
Accrued and other current liabilities
7,764
-5,856
-9,857
-4,110
Contract liabilities
-27,720
79,141
52,167
120,027
Operating lease liabilities, current and long-term
-6,898
-5,153
-4,553
-10,727
Other long-term assets and liabilities
-1,034
-658
-2,325
223
Cash provided by operating activities
74,382
120,112
94,749
162,124
Purchases of property and equipment
24,045
17,822
13,206
24,734
Consideration paid for acquisitions, net of cash acquired
-37
281,330
16,044
453
Proceeds from sale of property and equipment
87
133
164
226
Return of investment in joint venture
-
-
0
-
Cash used in investing activities
-23,921
-299,019
-29,086
-24,961
Term loan borrowings (including 2,968, 103,500, and 15,000 for the years ended december31, 2025, 2024, and 2023, respectively, from related parties)
-
-
2,968
-
Term loan borrowings (including 15,000 and 2,495 in 2026 and 2025, respectively, from related parties)
0
200,000
57,141
2,495
Term loan payments (including 74,797 in 2025 to related parties)
-
-
74,797
-
Term loan payments
2,489
2,494
57,141
795,073
Revolver borrowings
0
25,000
-
-
Revolver payments
0
25,000
-
-
Notes payable payments
1,368
1,905
1,776
6,102
Finance lease payments
1,567
1,288
1,149
2,694
Cash distributions to legence parent
-
-
0
0
Cash contributions from legence parent
-
-
0
0
Proceeds from ipo, net of underwriting discounts and commissions
-
-
0
780,243
Debt issuance costs
-
892
1,626
0
Payments of contingent consideration (including (20,663) and (5,520) for the years ended december31, 2024 and 2023, respectively, from related parties)
-
-
0
0
Payments for deferred offering costs
0
60
6,980
21,165
Other
1,431
-
-
-
Cash provided by (used in) financing activities
-3,101
193,361
-11,531
-42,296
Increase in cash and cash equivalents
47,360
14,454
54,132
94,867
Cash and cash equivalents, beginning of period
244,620
230,166
176,034
81,167
Cash and cash equivalents, end of period
291,980
244,620
230,166
176,034
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.